MEAs aim at early access to high-cost innovative medicines at pre-determined terms that can ensure the financial sustainability of healthcare systems. However, their successful adoption hinges on a consideration of various factors to address the unique challenges faced by different nations.

The aim of this document is to explore the concept of MEAs, understanding insights from existing literature regarding their benefits and challenges. Additionally, it seeks to formulate overarching recommendations for the implementation of MEAs in LMICs.